Table 3. Neoadjuvant therapy and perioperative parameters.
| Variables | ≥12 lymph nodes (N=53) (n, %) | <12 lymph nodes (N=38) (n, %) | P value |
|---|---|---|---|
| Chemotherapy* | χ2=1.613; P=0.20 | ||
| 5-FU infusion + leucovorin | 11 (44.0) | 9 (53.0) | |
| Oral capecitabine | 14 (56.0) | 8 (47.0) | |
| Radiotherapy dose (cGy) | χ2=1.467; P=0.48 | ||
| <5,000 | 7 (13.2) | 3 (7.9) | |
| 5,000–5,400 | 37 (69.8) | 29 (76.3) | |
| >5,400 | 9 (17.0) | 6 (15.8) | |
| Interrval to surgery (weeks with range) | 7 [4–11] | 8 [4–11] | 0.055 |
| Surgical approach | χ2=0.243; P=0.62 | ||
| Open | 48 (90.5) | 35 (92.0) | |
| Laparoscopic | 5 (9.5) | 3 (8.0) | |
| Surgical procedure | χ2=0.938; P=0.63 | ||
| LAR | 28 (52.8) | 18 (47.4) | |
| APR | 23 (43.4) | 18 (47.4) | |
| Exenteration | 2 (3.8) | 2 (5.2) |
*, means number of patients who had received chemotherapy along with radiotherapy.